IL122455A0 - Hapten modified tumor cell extract and methods of treating or screening for cancer - Google Patents

Hapten modified tumor cell extract and methods of treating or screening for cancer

Info

Publication number
IL122455A0
IL122455A0 IL12245596A IL12245596A IL122455A0 IL 122455 A0 IL122455 A0 IL 122455A0 IL 12245596 A IL12245596 A IL 12245596A IL 12245596 A IL12245596 A IL 12245596A IL 122455 A0 IL122455 A0 IL 122455A0
Authority
IL
Israel
Prior art keywords
cancer
tumor cell
modified tumor
screening
methods
Prior art date
Application number
IL12245596A
Other languages
English (en)
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of IL122455A0 publication Critical patent/IL122455A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/18Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
IL12245596A 1995-06-07 1996-06-06 Hapten modified tumor cell extract and methods of treating or screening for cancer IL122455A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47901695A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
IL122455A0 true IL122455A0 (en) 1998-06-15

Family

ID=23902311

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12245596A IL122455A0 (en) 1995-06-07 1996-06-06 Hapten modified tumor cell extract and methods of treating or screening for cancer

Country Status (11)

Country Link
EP (1) EP0837687B1 (pt)
JP (1) JPH11507633A (pt)
KR (1) KR19990022592A (pt)
AT (1) ATE386535T1 (pt)
AU (1) AU727316B2 (pt)
BR (1) BR9609026A (pt)
CA (1) CA2222135A1 (pt)
DE (1) DE69637440T2 (pt)
ES (1) ES2302337T3 (pt)
IL (1) IL122455A0 (pt)
WO (1) WO1996040173A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL328790A1 (en) * 1996-10-04 1999-02-15 Univ Jefferson T-lymphocytes provoking an immunological response and methods of using them
WO2000009140A1 (en) 1997-07-24 2000-02-24 Thomas Jefferson University Composition and method of using tumor cells
PL342856A1 (en) * 1998-02-17 2001-07-16 Univ Jefferson Hapten-modified tumor cell membranes, and methods of making and using hapten-modified tumor cell membranes
WO1999052546A2 (en) * 1998-04-09 1999-10-21 Thomas Jefferson University A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient
PL347981A1 (en) * 1998-05-04 2002-05-06 Univ Jefferson Composition comprising tumor cells and extracts and method of using thereof
US6248585B1 (en) 1998-11-19 2001-06-19 Thomas Jefferson University Compositions for preserving haptenized tumor cells for use in vaccines
WO2000031542A1 (en) * 1998-11-24 2000-06-02 Thomas Jefferson University Detection of t cell stimulating tumor antigens
AU2487500A (en) * 1998-12-30 2000-07-31 Thomas Jefferson University Dual hapten modified tumor cells and tumor polypeptides and methods of treating cancer
WO2000057911A2 (en) * 1999-03-16 2000-10-05 Thomas Jefferson University Hapten-conjugated mammalian cells and methods of making and using thereof
US7297330B2 (en) * 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy
US20040076646A1 (en) * 2001-07-18 2004-04-22 Caplan Michael J. Haptenizing cancer cell components
CA2489076A1 (en) 2002-06-10 2003-12-18 Avax Technologies Inc. Cryopreservation of haptenized tumor cells
US7598030B2 (en) * 2004-07-10 2009-10-06 Alexion Pharmaceuticals, Inc. Antibodies against cancer produced using masked cancer cells as immunogen
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2019165195A1 (en) 2018-02-22 2019-08-29 Srivastava Satish Combination therapy for the treatment of cancer
AU2019346403A1 (en) * 2018-09-24 2021-04-29 BioVaxys Inc. Bihaptenized autologous vaccines and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268640A4 (en) * 1986-05-07 1989-11-30 Sloan Kettering Inst Cancer VACCINE STIMULATING OR IMPROVING THE PRODUCTION OF ANTIBODIES AGAINST GM2.
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
GB2218420B (en) * 1988-04-12 1992-07-15 British Bio Technology Synthetic gene encoding interleukin 4
EP0466813A4 (en) * 1989-04-05 1992-07-15 Peter Y. S Fung Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins
US5290551A (en) * 1990-05-08 1994-03-01 Thomas Jefferson University Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
WO1995015334A1 (en) * 1993-11-30 1995-06-08 California Pacific Medical Center Research Institute cDNA PROBE FOR BREAST CANCER DIAGNOSIS AND TREATMENT
US7297330B2 (en) * 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy

Also Published As

Publication number Publication date
CA2222135A1 (en) 1996-12-19
AU6262096A (en) 1996-12-30
JPH11507633A (ja) 1999-07-06
DE69637440T2 (de) 2009-03-05
EP0837687A4 (en) 2001-06-27
KR19990022592A (ko) 1999-03-25
EP0837687B1 (en) 2008-02-20
MX9709733A (es) 1998-10-31
ES2302337T3 (es) 2008-07-01
WO1996040173A1 (en) 1996-12-19
DE69637440D1 (de) 2008-04-03
AU727316B2 (en) 2000-12-07
BR9609026A (pt) 1999-07-06
EP0837687A1 (en) 1998-04-29
ATE386535T1 (de) 2008-03-15

Similar Documents

Publication Publication Date Title
IL122455A0 (en) Hapten modified tumor cell extract and methods of treating or screening for cancer
NO932610L (no) Fremgangsmaate for behandling av tumornekrosefaktor formidlede sykdommer
WO2004016733A3 (en) Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
HK1024268A1 (en) Method for activating human antigen presenting cells, activated human antigen presenting cells, and use of the same.
GEP20002145B (en) Stem Cell Factor
CA2265464A1 (en) Therapy for .alpha.-galactosidase a deficiency
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
IL84211A0 (en) Tissue derived tumor growth inhibitors,methods of preparation and uses thereof
WO2000057911A3 (en) Hapten-conjugated mammalian cells and methods of making and using thereof
DE69720783D1 (de) Reaktive sauerstoffverbindungen enthaltende verbindungen zur induzierung von zelldifferentiation maligner zellen so wie leukämie
CA2098113A1 (en) Substances of polypeptide nature useful in human therapy
DE3684868D1 (de) Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
EP0839908A3 (en) A novel human ETS family member, ELF3
PT1573022E (pt) Ácido nucleico e proteína correspondente intitulada 184p1e2, utilizadas para o tratamento e detecção de cancro
ATE403716T1 (de) Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
DE19724546C2 (de) Pharmazeutische Zusammensetzung zur Behandlung von Krebs sowie Kit zur Herstellung dieser Zusammensetzung
RU93001102A (ru) Способ получения иммуномодулятора миелопида
WO2002014501A3 (en) Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer
WO2000022097A3 (en) Periferal blood mensenchymal precursor cells
RU93048507A (ru) Способ получения препарата, стимулирующего клеточное дыхание
Ishimori et al. Electrophoretic analysis of acid proteolytic zymogens in mucosa surrounding gastric ulcer
CA2261022A1 (en) System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
YU5002A (sh) Jedinjenja i postupci za lečenje i dijagnozu raka pluća
ATE533507T1 (de) Nukleinsäure und entsprechendes protein mit der bezeichnung 238p1b2, geeignet zur behandlung und zum nachweis von krebs
SU1622972A1 (ru) Способ хирургического лечения рака желудка